Keyphrases
Adenocarcinoma
100%
Paclitaxel
100%
Phase II Trial
100%
Group Studies
100%
Gynecologic Oncology Group
100%
Endometrium
100%
Recurrent Endometrial Cancer
40%
Response Rate
20%
Performance Status
20%
Anemia
20%
Neurotoxicity
20%
Chemotherapy
20%
Granulocyte Colony-stimulating Factor (G-CSF)
20%
Previously Treated
20%
In(III)
20%
Complete Response
20%
Partial Response
20%
Thrombocytopenia
20%
Measurable Disease
20%
Gastrointestinal Toxicity
20%
Cardiac Toxicity
20%
Group Performance
20%
Leukopenia
20%
Alopecia
20%
Pelvic Radiation
20%
Medicine and Dentistry
Adenocarcinoma
100%
Paclitaxel
100%
Gynecological Oncology
100%
Endometrium
100%
Phase II Trials
100%
Anemia
20%
Disease
20%
Pelvis
20%
Thrombocytopenia
20%
Gastrointestinal Toxicity
20%
Leukopenia
20%
Neurotoxicity
20%
Cardiotoxicity
20%
Alopecia Mucinosa
20%
Uterine Cancer
20%
Granulocyte Colony Stimulating Factor
20%
Chemotherapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
100%
Paclitaxel
100%
Phase II Trials
100%
Disease
20%
Anemia
20%
Chemotherapy
20%
Granulocyte Colony Stimulating Factor
20%
Neurotoxicity
20%
Thrombocytopenia
20%
Cardiotoxicity
20%
Endometrium Cancer
20%
Alopecia
20%
Leukopenia
20%
Gastrointestinal Toxicity
20%